[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652500":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":25,"responsibleParty":42,"collaborators":25,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":25,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":25,"enrollmentInfo":54,"targetDuration":25,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":69,"whyStopped":25,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":25},{"fullName":5,"class":6},"National Cheng-Kung University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group","EXPERIMENTAL","After 72 hours continuous intravenous PPI, patients in the intervention group will receive vonoprazon 20mg per day for 28 days.",[13],"Drug: Vonoprazon",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard group","ACTIVE_COMPARATOR","After 72 hours continuous intravenous PPI, patients in the intervention group will receive esomeprazole 40mg twice a day for 28 days.",[19],"Drug: Esomeprazole",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Vonoprazon",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Esomeprazole",[15],[30],{"name":31,"affiliation":5,"role":32},"Hsueh-Chien Chiang, MD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Meng-Hsuan Lu, MD","CONTACT","8862353535","cyes40327@gmail.com",{"name":31,"role":36,"phone":37,"phoneExt":40,"email":41},"9118","scion456scion@gmail.com",{"type":32,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Hsueh-Chien Chiang","Attending Physician","100652500","potassium-competitive-acid-blocker-versus-double-dose-proton-pump-inhibitors-in-high-high-risk-peptic-ulcer-bleeding-a-randomized-controlled-trial-100652500",false,"NCT07772700","Potassium-competitive Acid Blocker Versus Double Dose Proton Pump Inhibitors in High High-risk Peptic Ulcer Bleeding","Potassium-competitive Acid Blocker Versus Double Dose Proton Pump Inhibitors in High High-risk Peptic Ulcer Bleeding: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Hospitalized patients \\> 18 years with upper gastrointestinal ulcer bleeding, a Rockall score of 6 or higher, and treatment with endoscopic hemostasis.\n\nExclusion Criteria:\n\n* history of hypersensitivity to PPIs or P-CABs.\n* non-ulcer-related bleeding, such as variceal bleeding, angiodysplasia, diverticular bleeding, diffuse mucosal bleeding, or tumor bleeding.\n* severe hepatic or renal impairment","ALL","18 Years",{"count":55,"type":56},108,"ESTIMATED","INTERVENTIONAL",[59],"NA","This randomized clinical trial will enroll patients at National Cheng Kung University Hospital who have upper gastrointestinal ulcer bleeding, have undergone endoscopic hemostasis, and have a Rockall score of 6 or higher.\n\nA total of 108 patients will be enrolled and randomly assigned to two groups: Standard-treatment group: 54 patients, Experimental group: 54 patients.\n\nBoth groups will receive standard endoscopic hemostasis and 72 hours of intravenous PPI therapy. Thereafter, patients in the standard-treatment group will receive double-dose PPI therapy, whereas patients in the experimental group will receive a P-CAB per day. All patients will be followed for 28 days to assess the occurrence of rebleeding.",[62],"Bleeding",[64,65,66,67,68],"PCAB","PPI","peptic ulcer bleeding","Rockall score","rebleeding","NOT_YET_RECRUITING","2026-08-18",{"date":72,"type":73},"2026-08-20","ACTUAL",{"date":75,"type":56},"2026-09-01",{"date":77,"type":56},"2027-12-31",{"name":5,"class":6}]